Advanced and Metastatic Solid Tumors
Clinical research at Egle Therapeutics includes advanced and/or metastatic solid tumors, with attention to anti-cancer immunotherapy and treatment approaches for unmet oncologic needs. The sponsor’s oncology portfolio centers on adult patients with selected solid malignancies.
- Solid tumor oncology
- Metastatic cancer
- Immune-based cancer treatment
- Pembrolizumab combination therapy
This area reflects interest in tumor response, safety, and tolerability within oncology-focused drug development.
Atopic Dermatitis and Autoimmune Disease
The sponsor also funds research in atopic dermatitis and broader autoimmune disease settings, indicating a therapeutic focus on inflammatory skin disease and immune dysregulation. This includes work involving adults with autoimmune conditions.
- Atopic dermatitis
- Autoimmune disorders
- Inflammatory dermatology
- Immune-mediated disease
These studies place emphasis on therapeutic modulation of the immune system in chronic inflammatory disease.
First-in-Human Clinical Development
Egle Therapeutics is active in first-in-human clinical research, supporting early clinical exploration of novel therapeutics in both oncology and autoimmune disease. The sponsored program includes adult populations in multiple therapeutic settings.
- Early-stage clinical development
- Novel biologic therapies
- Adult patient populations
- Translational medicine
This research activity spans human safety assessment and initial evaluation of therapeutic activity across distinct disease areas.
Immunotherapy and Immune Regulation
The sponsor’s trial portfolio highlights interest in immune checkpoint-based treatment and other immune-regulating therapies. Its research spans both cancer immunology and autoimmune biology, reflecting a focus on targeted manipulation of immune pathways.
- Immune checkpoint therapy
- Cancer immunology
- Autoimmune immunology
- Targeted immune modulation
These programs connect oncologic therapy with inflammation-driven disease through shared immunological mechanisms.
